Estrella Immunopharma (ESLAW) Competitors $0.09 +0.00 (+3.61%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends ESLAW vs. ATNFW, SXTPW, DRTSW, WENAW, APLMW, BCTXW, CDIOW, CTCXW, CELUW, and CEROWShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Anew Medical (WENAW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Carmell (CTCXW), Celularity (CELUW), and CERo Therapeutics (CEROW). These companies are all part of the "biotechnology" industry. Estrella Immunopharma vs. 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Anew Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Carmell Celularity CERo Therapeutics Estrella Immunopharma (NASDAQ:ESLAW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, community ranking, analyst recommendations, profitability, earnings and media sentiment. Does the media refer more to ESLAW or ATNFW? In the previous week, Estrella Immunopharma's average media sentiment score of 0.00 equaled 180 Life Sciences'average media sentiment score. Company Overall Sentiment Estrella Immunopharma Neutral 180 Life Sciences Neutral Which has stronger valuation & earnings, ESLAW or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/AN/AN/AN/A180 Life SciencesN/AN/AN/AN/AN/A Is ESLAW or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A N/A N/A 180 Life Sciences N/A N/A N/A Does the MarketBeat Community believe in ESLAW or ATNFW? Estrella Immunopharma and 180 Life Sciences both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformEstrella ImmunopharmaN/AN/A180 Life SciencesN/AN/A SummaryEstrella Immunopharma and 180 Life Sciences tied by winning 0 of the 0 factors compared between the two stocks. Ad Weiss RatingsNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLAW and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLAW vs. The Competition Export to ExcelMetricEstrella ImmunopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$165.68M$5.14B$9.08BDividend YieldN/A3.64%5.09%4.23%P/E RatioN/A115.5190.1317.19Price / SalesN/A18,531.021,116.25117.05Price / CashN/A12.8743.1037.85Price / BookN/A8.594.784.78Net IncomeN/A-$20.67M$120.31M$225.60M7 Day PerformanceN/A-1.05%-1.92%-1.23%1 Month PerformanceN/A174.77%13.65%0.46%1 Year PerformanceN/A134.18%28.34%15.24% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAWEstrella ImmunopharmaN/A$0.09+3.6%N/A+31.3%$0.00N/A0.00N/AATNFW180 Life SciencesN/A$0.01-8.5%N/A+31.6%$0.00N/A0.007Positive NewsGap DownSXTPW60 Degrees PharmaceuticalsN/A$0.02-50.8%N/A-56.7%$0.00$502,409.000.002Positive NewsGap DownHigh Trading VolumeDRTSWAlpha Tau MedicalN/A$0.20-18.5%N/A+68.4%$0.00N/A0.0080Positive NewsGap DownWENAWAnew MedicalN/A$0.04-0.3%N/AN/A$0.00N/A0.00N/AGap DownAPLMWApollomicsN/A$0.01-16.5%N/A-45.9%$0.00N/A0.0059News CoverageGap UpBCTXWBriaCell TherapeuticsN/A$0.32-20.6%N/A-82.3%$0.00N/A0.008CDIOWCardio DiagnosticsN/A$0.13+21.4%N/A-34.7%$0.00$35,688.000.007Positive NewsGap UpHigh Trading VolumeCTCXWCarmellN/A$0.03-47.8%N/AN/A$0.00$32,839.000.009Positive NewsGap DownCELUWCelularityN/A$0.02+7.3%N/A-19.6%$0.00$48.20M0.00220Positive NewsGap UpCEROWCERo TherapeuticsN/A$0.02+25.0%N/AN/A$0.00N/A0.008Gap Down Related Companies and Tools Related Companies 180 Life Sciences Competitors 60 Degrees Pharmaceuticals Competitors Alpha Tau Medical Competitors Anew Medical Competitors Apollomics Competitors BriaCell Therapeutics Competitors Cardio Diagnostics Competitors Carmell Competitors Celularity Competitors CERo Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ESLAW) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ESLAW Stock Alerts